Neurological Disease clinical trials

Explore recruiting neurological disease clinical trials.

Recruiting neurological disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neurological Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-Label, Multicenter Extension Study Providing Continued Access to Treatment in Patients with a Neurological Disease Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study and without Access to A Post Trial Access Program

Czechia, France, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1, Randomized, Double-Blind, Placebo-Controlled study to Evaluate the Safety, Tolerability,and Pharmacokinetics of Single and Multiple Ascending Doses of CBT101 given intranasally in Healthy Male Subjects.

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Influence of Dexmedetomidine on the Human Glymphatic Cerebrospinal Fluid Flow, Neural Activity and Cerebral Blood Flow in Functional Magnetic Resonance Imaging (GlymphDex)

Finland

Therapeutic exploratory (Phase II) EU CTIS Study details

Quantification tools for a novel tau PET marker in a rare neurological disease: 18F-PI-2620 in progressive supranuclear palsy

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Open label, Multicenter, Prospective Study to Characterize the Pharmacokinetics and Pharmacodynamics of Cufence (Trientine Dihydrochloride) and to Investigate the Efficacy and Safety in Wilson’s Disease Patients

Germany, France, Denmark, Poland

Therapeutic use (Phase IV) EU CTIS Study details

Neurological Disease trials by city

Neurological Disease in Toronto Neurological Disease in Vancouver Neurological Disease in Montreal Neurological Disease in Calgary Neurological Disease in Edmonton Neurological Disease in Ottawa Neurological Disease in Winnipeg Neurological Disease in Quebec City Neurological Disease in Hamilton Neurological Disease in Kitchener Neurological Disease in London Neurological Disease in Halifax Neurological Disease in New York Neurological Disease in Los Angeles Neurological Disease in Chicago Neurological Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease